Cart
sales@molnova.com
SB 328437
CAS No. 247580-43-4
SB 328437( (S)-methyl 2-(1-naphthamido)-3-(4-nitrophenyl)propanoate | ZINC29222893 )
Catalog No. M27704 CAS No. 247580-43-4
SB 328437 is an effective and selective antagonist of CCR3 (IC50 = 4.5 nM).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 87 | In Stock |
|
| 10MG | 140 | In Stock |
|
| 25MG | 282 | In Stock |
|
| 50MG | 462 | In Stock |
|
| 100MG | 672 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSB 328437
-
NoteResearch use only, not for human use.
-
Brief DescriptionSB 328437 is an effective and selective antagonist of CCR3 (IC50 = 4.5 nM).
-
DescriptionSB 328437 is an effective and selective antagonist of CCR3 (IC50 = 4.5 nM).
-
In Vitro——
-
In Vivo——
-
Synonyms(S)-methyl 2-(1-naphthamido)-3-(4-nitrophenyl)propanoate | ZINC29222893
-
PathwayAutophagy
-
TargetCCR
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number247580-43-4
-
Formula Weight378.38
-
Molecular FormulaC21H18N2O5
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 125 mg/mL (330.36 mM)
-
SMILESCOC(=O)[C@H](Cc1ccc(cc1)[N+]([O-])=O)NC(=O)c1cccc2ccccc12
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Stefanie Flohr, et al. 5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors. WO2013111108A1
molnova catalog
related products
-
CCR2 antagonist 5
CCR2 antagonist 5 (JNJ-41443532) is a selective and orally active hCCR2 inhibitor with good binding affinity (IC50=37 nM) and potent functional antagonism (chemotaxis IC50=30 nM).
-
GSK2239633A
GSK2239633A is an allosteric antagonist of CC-chemokine receptor 4 (CCR4) with a pIC50 of 7.96 for the binding of [125I]-TARC to human CCR4.
-
Plozalizumab
Plozalizumab (MLN-1202) is a humanized, selective, and potent anti-CCR2 antibody with antitumor activity, used in the study of malignant melanoma.
